CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology
Longeveron Inc. (NASDAQ: LGVN) announced that CEO Geoff Green will present on "A Regenerative Medicine Approach to Aging Frailty" at the Intercontinental Summit on Aging & Gerontology on March 8, 2021. The virtual summit, hosted by the Sciinov Group, aims to unite researchers and scientists to discuss advancements in Aging & Gerontology. Longeveron is focused on developing cellular therapies for aging-related conditions, including Alzheimer’s disease and Aging Frailty, through its investigational product LOMECEL-B™.
- None.
- None.
MIAMI, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Green, Chief Executive Officer of Longeveron, has been invited to give a presentation titled “A Regenerative Medicine Approach to Aging Frailty” at the Intercontinental Summit on Aging & Gerontology being held virtually on March 8, 2021. He will discuss Longeveron’s ongoing clinical research program in Aging Frailty and Alzheimer’s disease, in addition to the regenerative medicine investigational clinical research field in general for diseases and conditions associated with aging.
The Intercontinental Summit on Aging & Gerontology is hosted by the Sciinov Group and helps participants from universities and institutions to network with world-class scientists. This all-day online event unites researchers, scientists, and academicians to discuss and share knowledge in the emerging field of Aging & Gerontology.
Information about the event can be found by visiting: agingcongress.com. A copy of the Company’s presentation will also be available on the Company’s website at: www.longeveron.com.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements that reflect management's current expectations, assumptions, and estimates of future performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as "believe," "expects," "may," "looks to," "will," "should," "plan," "intend," "on condition," "target," "see," "potential," "estimates," "preliminary," or "anticipates" or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Moreover, forward-looking statements in this release include, but are not limited to, statements about the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials; the size of the market opportunity for our product candidates, the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates, our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others. Further information relating to factors that may impact the Company's results and forward-looking statements are disclosed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: lgvn@crescendo-ir.com
FAQ
What is the purpose of the Intercontinental Summit on Aging & Gerontology on March 8, 2021?
Who is presenting on Aging Frailty at the Intercontinental Summit?
What is Longeveron Inc.'s focus in clinical research?
What is LOMECEL-B™?
Where can I find more information about Longeveron Inc.?
